CDEK
← All drugs Report issue

bethanechol

Trade name: urecholine

Small moleculeapproved

Approved

Oct 12, 1948

Bethanechol is a parasympathomimetic choline carbamate that selectively stimulates muscarinic receptors with little effect on nicotinic receptors. Bethanechol is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. — NCATS

Clinical trial activity

7 trials · 7 clinical orgs · 22 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
1

Earliest trial started Nov 1, 2009 (NCT01031043)

Timeline

1940s

  1. Oct 12, 1948

    Merck — Earliest FDA Approval

  2. Oct 12, 1948

    Odyssey Pharmaceuticals — NDA Secondary Org

  3. Oct 12, 1948

    Merck — NDA Organization

1970s

  1. Nov 11, 1974

    Watson Pharmaceuticals — Marketing Organization

  2. Jul 29, 1975

    Lannett Company, Inc. — Marketing Organization

  3. Sep 24, 1975

    Glenwood Pharmaceuticals — Marketing Organization

  4. Dec 16, 1975

    Teva — Marketing Organization

  5. Mar 22, 1978

    Bi-Coastal Pharma — Marketing Organization

  6. Mar 22, 1978

    Chartwell Pharmaceuticals — Marketing Organization

1980s

  1. Nov 4, 1982

    Sandoz — Marketing Organization

  2. May 29, 1984

    Odyssey Pharmaceuticals — Marketing Organization

2000s

  1. Sep 29, 2003

    Wockhardt — Marketing Organization

  2. Jul 27, 2004

    Able Laboratories — Marketing Organization

  3. Oct 28, 2004

    Actavis — Marketing Organization

  4. Jun 1, 2005

    Upsher-Smith Laboratories — Marketing Organization

  5. Nov 1, 2006

    Impax Laboratories — Marketing Organization

  6. Oct 26, 2007

    Aderis — Marketing Organization

  7. Oct 26, 2007

    Eci Pharmaceuticals Llc — Marketing Organization

  8. Oct 26, 2007

    TTY Biopharm — Marketing Organization

  9. Nov 21, 2007

    Amneal Pharmaceuticals — Marketing Organization

  10. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

  11. Apr 22, 2009

    Sun Pharmaceuticals — Marketing Organization

2010s

  1. May 4, 2010

    Heritage Pharma — Marketing Organization

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedOct 12, 1948

Chemistry & pharmacology

Loading structure…

SMILES

CC(C[N+](C)(C)C)OC(N)=O
Mol. weight
161.22 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2-(carbamoyloxy)-n,n,n-trimethylpropan-1-aminium
  • 2-(carbamoyloxy)-n,n,n-trimethylpropan-1-aminium
  • 2-carbamoyloxypropyl-trimethylazanium
  • 2-carbamoyloxypropyl-trimethylazanium
  • (2-hydroxypropyl)trimethylammonium carbamate
  • (2-hydroxypropyl)trimethylammonium carbamate
  • amidopropyldimethylbetaine
  • amidopropyldimethylbetaine
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol
  • bethanechol chloride
  • bethanechol chloride
  • bethanechol chloride
  • bethanechol chloride
  • bethanechol chloride
  • carbamoyl-beta-methylcholine
  • carbamoyl-beta-methylcholine
  • carbamoyl-beta-methylcholine
  • carbamoyl-β-methylcholine
  • carbamoyl-β-methylcholine
  • carbamyl-beta-methylcholine
  • carbamyl-beta-methylcholine
  • carbamyl-beta-methylcholine
  • carbamylmethylcholine chloride
  • carbamylmethylcholine chloride
  • carbamyl-β-methylcholine
  • carbamyl-β-methylcholine
  • duvoid
  • duvoid
  • liberan
  • myocholine
  • myocholine
  • myotonachol
  • myotonachol
  • myotonine
  • myotonine
  • urecholine
  • urecholine
  • urecholine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06471868Phase 1Jun 10, 2024Il-Yang Pharm. Co., Ltd.
NCT05241249Phase 2Feb 1, 2022Columbia University
NCT03572283Early Phase 1 (Phase 1)Apr 8, 2018Columbia University
NCT02910596Phase 4Oct 1, 2016Rajavithi Hospital, Bangkok
NCT02058537Phase 2Feb 1, 2014University of Iowa
NCT01434901Phase 1Aug 15, 2011National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Washington University in St. Louis
NCT01031043Phase 1Nov 1, 2009Augusta University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Columbia UniversityAcademic/Hospital2222018
Augusta UniversityAcademic/Hospital1112009
Il-Yang Pharm. Co., Ltd.For profit1112024
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012011
Rajavithi Hospital, BangkokAcademic/Hospital1112016
University of IowaAcademic/Hospital1112014
Washington University in St. LouisAcademic/Hospital1112011
7 organizations
Page 1 / 1

Marketing (25)

OrganizationOrg typeRelationshipDate
Able LaboratoriesFor profitMKTGJul 27, 2004
ActavisFor profitMKTGOct 28, 2004
AderisFor profitMKTGOct 26, 2007
Amneal PharmaceuticalsFor profitMKTGNov 21, 2007
Ascot PharmaceuticalsFor profitMKTG—
Athenex, Inc.For profitMKTG—
Bi-Coastal PharmaFor profitMKTGMar 22, 1978
Chartwell PharmaceuticalsFor profitMKTGMar 22, 1978
Eci Pharmaceuticals LlcFor profitMKTGOct 26, 2007
Glenwood PharmaceuticalsFor profitMKTGSep 24, 1975
Heritage PharmaFor profitMKTGMay 4, 2010
Impax LaboratoriesFor profitMKTGNov 1, 2006
Lannett Company, Inc.For profitMKTGJul 29, 1975
Lannett Company, Inc.For profitSYNMar 27, 2008
MerckFor profitNDAOct 12, 1948
Odyssey PharmaceuticalsFor profitNDA2Oct 12, 1948
Odyssey PharmaceuticalsFor profitMKTGMay 29, 1984
SandozFor profitMKTGNov 4, 1982
Sun PharmaceuticalsFor profitMKTGApr 22, 2009
TTY BiopharmFor profitMKTGOct 26, 2007
TevaFor profitMKTGDec 16, 1975
TevaFor profitSYNOct 12, 1948
Upsher-Smith LaboratoriesFor profitMKTGJun 1, 2005
Watson PharmaceuticalsFor profitMKTGNov 11, 1974
WockhardtFor profitMKTGSep 29, 2003